Hepaxa(TM)
Natural health product licensed in Canada
- Other names
- Hepaxa(TM) PD
- Licence holder
- BASF AS
- NPN or DIN-HM
- 80096048
- Status
- Inactive licence
- Licence date
- 11 December 2019
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Non traditionnelle
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| Huile de poisson Source : Poisson d'huile de poisson - en entier Potency : 260 mg Docosahexaenoic acid | 675 mg | Not calculated |
| Huile de poisson Source : Poisson d'huile de poisson - en entier Potency : 323 mg Eicosapentaenoic acid | Not specified | Not calculated |
Non-medicinal ingredients
Mélange de concentré de tocophérols, Eau purifiée, Gélatine, Huile minérale, Glycérine
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Enfants | minimum: 10 years ; maximum: 18 years | minimum: 1 Capsule ; maximum: 2 Capsule | 1 Tous les jours |
| Adultes | minimum: 19 years | 4 Capsule | 1 Tous les jours |
Uses authorised in Canada
Helps support cognitive health and/or brain function. Helps maintain/support cardiovascular health. Source of omega-3 fatty acids for the maintenance of good health. Recommended to be used as supportive therapy for the management of hepatic steatosis/non-alcoholic fatty liver disease (NAFLD) in combination with a healthy diet, reduced caloric intake and regular exercise. Recommended to be used as an adjunct to a healthy diet, reduced caloric intake and regular exercise for the management of hepatic steatosis/non-alcoholic fatty liver disease (NAFLD). Recommended to be used in conjunction with a healthy diet, reduced caloric intake and regular exercise for the management of hepatic steatosis/non-alcoholic fatty liver disease. Recommended to be used for the dietary management of hepatic steatosis/non-alcoholic fatty liver disease (NAFLD) in conjunction with a healthy diet, reduced caloric intake and regular exercise.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
No French warning text available in the imported data.
Warnings are available in English on the official record.
Source
Official Health Canada record, licence 80096048
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.